Navigation Links
A new male contraceptive

According to researchers it is observed that a drug already being used to treat a rare genetic disorder may also be an effective male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has been approved in Europe to treat Gaucher's disease, might work// as a male contraceptive because it affects the metabolism of sugar-fat compounds essential for male fertility. They tested their theory in an animal study involving mice. The mice were given doses of the drug that were 10-times lower than those used to treat Gaucher's. The drug effectively altered the mice's sperm so that they were rendered completely infertile for up to six months. After they were taken off the drug, fertility returned completely to normal.

Since NB-DNJ is not a hormonal treatment, the sex drive of the mice was not impacted by the treatment. Few unwanted side effects were noted. Because the dose needed to induce infertility was so much lower than the standard dose given humans for Gaucher's disease, the investigators believe side effects in men would be negligible.

The investigators suggest this drug has significant potential to serve as a safe and effective a male contraceptive in humans. They write, "Considering the advanced status of NB-DNJ in clinical application, this compound could be rapidly evaluated for its suitability as a male contraceptive."


'"/>




Page: 1

Related medicine news :

1. Another injectable contraceptive Pill approved by FDA
2. Male contraceptive in trial
3. Hormone contraceptives lead to bone problems
4. A new contraceptive
5. Spray on contraceptive clears Phase I trial
6. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
7. Lower doses of oral contraceptives helpful in treating acne
8. Dermaseptins: Potent vaginal contraceptives
9. Oral contraceptives safe for women with Lupus erythematosus
10. Islamic Medical Ethics opposes Irreversible contraceptive and surrogate motherhood.
11. The conception of Anya, a period-free contraceptive pill
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: